The Record-Chronicle spoke with more than a dozen people with ties to the program, including donors, school officials, ...

Architectural products company Apogee (NASDAQ:APOG) will be reporting results tomorrow before market open. Here’s what to look for. Apogee beat analysts’ revenue expectations by 2.8% last ...

Shares of architectural products company Apogee (NASDAQ:APOG) fell 10.7% in the morning session after the company reported mixed first-quarter 2025 results: Looking ahead, the full-year earnings ...

Its guidance for the current fiscal year wasn't inspiring, either. Much of this was due to the fact that Apogee posted declines in key fundamentals; net sales were down by nearly 5% year over year ...

It believes Apogee will earn $1.37 billion to $1.43 billion in net sales, while operating income per share should come in at $3.55 to $4.10. The respective numbers for fiscal 2025 were $1.36 ...

APG808 cut FeNO by 53% at week 12, with sustained 50% reduction, showing anti-inflammatory effect. No Grade 3 or severe adverse events; most common side effects included headache and mild ...

SAN FRANCISCO--(BUSINESS WIRE)--RSAC – Apogee Global RMS, the transformative talent and leadership development company, today announced the addition of two high-profile executives to its team.

MINNEAPOLIS--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG) announced today that its Board of Directors has declared a quarterly cash dividend of $0.26 per share. The dividend will be ...

On April 24, Matthew J Osberg, EVP and CFO at Apogee Enterprises APOG executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: A Form 4 filing with the U.S ...

Apogee Enterprises Inc. (APOG) reported its earnings for the second quarter of 2025, revealing a mixed financial performance. The company posted earnings per share (EPS) of $0.89, falling short of ...

SAN FRANCISCO and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for ...